Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro
2006 (English)In: Cell Biology International, ISSN 1065-6995, E-ISSN 1095-8355, Vol. 30, no 12, 1013-1017 p.Article in journal (Refereed) Published
The tyrosine kinase inhibitor imatinib mesylate (Gleevec) has been demonstrated to protect various cell types from death by inhibition of Abelson tyrosine kinase (c-Abl). The aim of the present study was to establish whether imatinib protects the insulin producing β-cell from the different apoptosis promoting agents in vitro and whether imatinib counteracts streptozotocin-induced diabetes in NMRI mice. We observe that imatinib attenuated the actions of several different death promoting substances. In addition, mice injected with streptozotocin did not develop diabetes when given imatinib. The beneficial effects of imatinib may be related to inhibition of the pro-apoptotic MAP kinase JNK. We conclude that imatinib protects against β-cell death and that this may contribute to the previously reported anti-diabetic actions of imatinib.
Place, publisher, year, edition, pages
2006. Vol. 30, no 12, 1013-1017 p.
Apoptosis, Diabetes, Imatinib, JNK, Pancreatic islet
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-94676DOI: 10.1016/j.cellbi.2006.08.006ISI: 000242714100009PubMedID: 17020808OAI: oai:DiVA.org:uu-94676DiVA: diva2:168621